Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

See allHide authors and affiliations

Sci. Signal.  05 Feb 2019:
Vol. 12, Issue 567, eaau2922
DOI: 10.1126/scisignal.aau2922

Targeted epigenetic therapy for SCLC

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with no targeted therapeutic options and in which chemotherapy is only partially effective. Previous studies indicated that SCLC growth is suppressed by drugs that inhibit the histone lysine demethylase LSD1. Augert et al. found that LSD1 epigenetically suppressed the expression of the gene encoding NOTCH1, enabling the activity of the neuroendocrine cell lineage–associated transcription factor ASCL1. Blocking LSD1 with iadademstat (ORY-1001), a drug that has just been approved for phase 2 clinical trials in leukemia, reactivated NOTCH signaling and suppressed ASCL1 activity, inhibiting tumor growth and even inducing complete tumor regression in a patient-derived mouse model of SCLC.


Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcription factor ASCL1 and the repression of SCLC tumorigenesis. Our analyses revealed that LSD1 bound to the NOTCH1 locus, thereby suppressing NOTCH1 expression and downstream signaling. Reactivation of NOTCH signaling with the LSD1 inhibitor reduced the expression of ASCL1 and neuroendocrine cell lineage genes. Knockdown studies confirmed the pharmacological inhibitor-based results. In vivo, sensitivity to LSD1 inhibition in SCLC patient-derived xenograft (PDX) models correlated with the extent of consequential NOTCH pathway activation and repression of a neuroendocrine phenotype. Complete and durable tumor regression occurred with ORY-1001–induced NOTCH activation in a chemoresistant PDX model. Our findings reveal how LSD1 inhibitors function in this tumor and support their potential as a new and targeted therapy for SCLC.


Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma characterized by initial chemosensitivity, followed by the rapid emergence of chemoresistance (1). There has been limited improvement in first-line SCLC treatment in the past 30 years, and no targeted therapies are currently available. The high death rate and lack of treatment options have led the National Cancer Institute to designate SCLC as a “Recalcitrant Cancer” to underscore the need for new therapeutic frameworks. SCLC does not harbor frequent mutations in “druggable” oncogenic drivers or tumor suppressors (24). Instead, this neuroendocrine tumor type co-opts the same transcriptional programs necessary for normal lung neuroendocrine cell development to sustain tumor cell growth. (5, 6), and the deletion of Ascl1 strongly suppresses tumorigenesis in a genetically engineered mouse model of SCLC (5). During lung development, NOTCH signaling negatively regulates ASCL1 (6), and the activation of NOTCH family members also potently suppresses SCLC in mouse models (2). Knowledge of these genetic dependencies has not clinically affected the progression of SCLC, given the challenges of activating NOTCH or suppressing ASCL1 using conventional pharmacological approaches. SCLC exhibits frequent mutations in chromatin-regulating genes (24), leading to proposals to target the altered epigenetic landscapes of SCLC for therapeutic vulnerabilities. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) is a flavin adenine dinucleotide–dependent demethylase that is highly expressed in SCLC (7) and demethylates the monomethylated and dimethylated forms of histone H3 at lysine 4 (H3K4me1 and H3K4me2) (8). The demethylation of H3K4me1 has been linked to the decommissioning of transcriptional enhancers in embryonic stem cells (9). LSD1 is a component of multiple large repressive complexes, including CoREST [cofactor of RE1-silencing transcription factor (REST)] and NuRD (nucleosome remodeling and histone deacetylase), coordinating histone acetylation and methylation to control target gene transcription (10, 11). In preclinical studies, LSD1 inhibition exhibits selective activity in acute myeloid leukemia (AML) and SCLC models, which led to the subsequent clinical evaluation of LSD1 inhibitors in these respective indications (7, 12, 13). However, the mechanism of action underlying LSD1 inhibitor efficacy in SCLC remained elusive. In this study, we evaluated the mechanism of action of LSD1 inhibitor ORY-1001 (also known as iadademstat, formerly RG6016), a novel, highly potent, orally available and irreversible LSD1 inhibitor that exhibits strong selectivity for LSD1 over LSD2 and monoamine oxidase enzymes (12). Our findings revealed that LSD1 inhibition modulates the NOTCH-ASCL1 axis to suppress SCLC tumorigenesis.


ORY-1001 is antiproliferative in a subset of SCLC cell lines

Screening of ORY-1001 across a broad panel of 275 cell lines representing 14 tumor histologies resulted in antiproliferative activity in a subset of SCLC and AML cell lines (Fig. 1A). This finding is similar to the reported effects of LSD1 inhibitor GSK2879552 (7). The activity of ORY-1001 was assessed in a larger panel of SCLC cell lines. ORY-1001 induced growth inhibition in a subset of SCLC cell lines, corresponding to antiproliferative half-maximal effective concentration (EC50) values within the subnanomolar to nanomolar range (table S1). Four responsive SCLC cell lines (NCI-H510A, NCI-H1417, NCI-H146, and NCI-H187) were treated with ORY-1001, and RNA sequencing (RNA-seq) analyses were performed. ORY-1001 treatment resulted in 1400 differentially expressed genes [false discovery rate (FDR), <0.05] (table S2). Pathway analyses using Enrichr (14) revealed enrichment in NOTCH pathway genes and in gene sets related to neuronal differentiation and signaling after ORY-1001 treatment (Fig. 1B). The expression of multiple NOTCH family member genes and NOTCH target genes was up-regulated upon ORY-1001 treatment, whereas that of ASCL1, a target that is negatively regulated by NOTCH, decreased (Fig. 1C). Thus, LSD1 inhibition modulated the expression of key neuroendocrine genes, specifically a decrease in ASCL1 and an increase in the expression of NOTCH family members and downstream targets (Fig. 1C).

Fig. 1 ORY-1001 exhibits antiproliferative activity in a subset of SCLC cell lines.

(A) Antiproliferative activity of ORY-1001 (in concentrations of up to 10 μM) was screened across a panel of 275 cell lines in a 4-day cell viability assay (CellTiter-Glo). EC50 values in responsive cell lines ranged from 0.1 to 23 nM. NSCLC, nonsmall cell lung cancer. GI, gastrointestinal. (B) RNA-seq analyses performed using DeSeq2 (47) in SCLC cell lines (NCI-H146, NCI-H187, NCI-H510A, and NCI-H1417) treated with 10 nM ORY-1001 for 96 hours. Differentially expressed genes (1400; table S2) with FDR < 0.05 were used for enrichment analysis with the online tool Enrichr (14), assigned according to the PANTHER and Gene Ontology (GO) biological process databases. For the PANTHER pathways listed, all significant pathways with FDR < 0.05 are shown. For GO biological processes, a subset of significant processes with FDR < 0.05 are shown, including Notch signaling (GO:0007219). (C) Heat map showing differentially expressed genes in Notch pathway (GO:0007219), showing log 2 fold change (FC) in ORY-1001–treated relative to vehicle-treated cells.

ORY-1001 up-regulates NOTCH and REST while suppressing ASCL1

Because long-term culture and passage of cell lines can lead to irreversible changes (15), the selective responses to ORY-1001 were further explored in clinically relevant patient-derived xenograft (PDX) SCLC models cultured transiently ex vivo. PDX explants, previously passaged only as xenografts in mice, were briefly plated in tissue culture and exposed to ORY-1001 ex vivo. The collection of PDX models used for ex vivo studies included three novel models; FHSC04 and FHSC14 were generated from SCLC patient circulating tumor cells (CTCs), and MSK-LX227C was generated from transbronchial needle biopsy. Images from our CTC-derived PDX model is shown in fig. S1. The remaining PDX models used have been previously described (1518), and the properties of all the PDX models are shown in table S3. These SCLC PDX cell models survived and proliferated ex vivo. Cultured FHSC04 cells were found to be markedly sensitive to ORY-1001 treatment with an IC50 (median inhibitory concentration) of 13 nM (Fig. 2A). For all other PDX cells examined ex vivo, the IC50 for ORY-1001 was above 1 μM (Fig. 2A). FHSC04 grows as a mixed population of cell clusters and adherent neuroendocrine cells; morphological changes consistent with cell death occurred at 96 hours after treatment of the suspension cell population with 1 nM ORY-1001 (Fig. 2B, bottom). These observations were consistent with increased detection of cleaved caspase 3 and cleaved poly(adenosine diphosphate–ribose) polymerase (PARP) at this time point (Fig. 2B, top). In contrast, models with lower sensitivity to ORY-1001 (JHU-LX48 and JHU-LX108) retained viable cell clusters at 96 hours of treatment with no evidence of apoptosis based on cell morphology and Western blot analysis of cleaved caspase 3 and PARP (Fig. 2, C and D).

Fig. 2 LSD1 inhibition with ORY-1001 results in the activation of NOTCH signaling.

(A) Dose-response curves of seven PDX model–derived cells cultured and treated ex vivo with ORY-1001 for 120 hours. Viability was assessed with the CellTiter-Glo assay and calculated relative to the vehicle control. Data are means ± SEM from at least n = 3 biological replicates. (B) Immunoblots (top) and photomicrographs (bottom) for FHSC04 cells treated ex vivo with ORY-1001. Protein abundance was assessed at 48, 72, and 96 hours of 1 nM ORY-1001 treatment, and photomicrographs were taken at 96 hours. Blots are representative of two independent experiments. c-CASP3, cleaved caspase 3. Scale bars, 100 μM. (C and D) As described in (B) for JHU-LX48 (C) and JHU-LX108 (D) cells. As a positive control for cleaved caspase 3 and PARP, lysates from FHSC04 cells treated for 96 hours with 1 nM ORY-1001 [also represented in (B)] was run on the same blot (“+” lane). Blots are representative of two independent experiments. (E) RNA-seq MA plot showing differentially expressed genes across the seven PDX models treated ex vivo with 1 nM ORY-1001. Red, up-regulated genes; green, down-regulated genes; each with log 2 fold change > 0.585 and FDR < 0.05 as identified using edgeR. CPM, counts per million. (F) Gene Ontology analysis using GOseq (19) showing the top 6 significant GO terms in the genes differentially expressed with FDR < 0.05 (see Methods and table S4 for full list). (G) Abundance of NOTCH1, REST, and ASCL1 transcripts in the PDX models ex vivo assessed using real-time PCR, with expression plotted relative to that of GAPDH (n = 3 independent experiments). (H) Immunoblot showing kinetics of changes in NOTCH1, NOTCH2, REST, and ASCL1 protein abundance in the drug-sensitive FHSC04 model treated ex vivo with 1 nM ORY-1001 for 120 hours. Data are means ± SD from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.005 by a two-tailed unpaired Student’s t test. ACTB, beta actin.

To identify LSD1-regulated signaling pathways that may contribute to observed responses, we analyzed transcriptional changes in the panel of PDX models treated with 1 nM ORY-1001 ex vivo. Cells were treated for 48 hours, a time point that precedes cell death in treated FHSC04 cells (Fig. 2B). edgeR analyses revealed 518 differentially expressed genes upon ORY-1001 treatment: 289 up-regulated and 229 down-regulated (FDR, <0.05) (Fig. 2E and table S4). Consistent with the cell line models, gene ontology analyses using GOseq (19) revealed strong enrichment in NOTCH signaling pathways (e.g., NOTCH1, NOTCH2, HES1, HEY1, DLL1, DLL3, and DLL4) and neuron fate specification (e.g., ASCL1, POU4F1, EYA1, and NKX2-2) (Fig. 2F and table S5). Similar directional changes in NOTCH1, HES1, REST, and ASCL1 occurred in almost all of the models, although the magnitude of these changes was greatest in FHSC04, as shown by both real-time polymerase chain reaction (PCR) analyses (Fig. 2G) and fragment per kilobase per million (FPKM) values from the RNA-seq analyses (fig. S2). NOTCH1 has been previously shown to suppress ASCL1 (20, 21), a master regulator of neuroendocrine cell fate recently found to be essential for SCLC cell survival/viability (5). It has also been shown that REST, a repressor of neural gene expression, is a direct target of NOTCH1 and that REST up-regulation contributes to NOTCH-mediated ASCL1 suppression in SCLC (21). After LSD1 inhibition with ORY-1001, we observed an increase in REST transcripts most prominently in the FHSC04 model (Fig. 2G). We next examined the kinetics of changes in ASCL1 and negative regulators of ASCL1 using Western blot analysis in the sensitive FHSC04 model. A sharp drop in ASCL1 protein abundance occurred with an increase in active NOTCH1 intracellular domain (N1ICD) and REST protein abundance by 20 hours of ORY-1001 treatment (Fig. 2H). Increases in the NOTCH2 intracellular domain (N2ICD) were delayed relative to N1ICD, being observed after 48 hours of ORY-1001 treatment (Fig. 2H). Further evidence of NOTCH pathway activation upon LSD1 inhibition included the induction of NOTCH1 target gene HES1 (Fig. 2H).

LSD1 inhibition results in altered H3K27Ac at key target genes

As transcriptional data revealed NOTCH pathway activation in sensitive SCLC models, we followed with chromatin immunoprecipitation with high-throughput sequencing (ChIP-seq) analyses to evaluate the mechanism of NOTCH pathway deregulation in response to LSD1. We used antibodies to LSD1 and to key histone modification marks in SCLC cell lines, after 96-hour treatment with 1 nM ORY-1001 or vehicle control. We focused on the ORY-1001–responsive cell line NCI-H510A and the less sensitive NCI-H526 cell line. LSD1 demethylates H3K4, and changes in H3K4 dimethylation (H3K4me2) can be found in putative LSD1 target genes in some cell types after LSD1 knockdown or inhibition (2224). However, in the SCLC cells examined, ChIP-seq analysis revealed that increased mRNA expression of NOTCH1 with ORY-1001 treatment in NCI-H510A cells was not associated with changes in locus-specific H3K4me2 deposition (Fig. 3A). LSD1 is a component of the CoREST complex that also includes histone deacetylases (HDAC1 and HDAC2) (25). This led to an evaluation of histone acetylation marks in response to LSD1 inhibition. We detected an increased abundance of histone H3K27 acetylation (H3K27Ac) along the NOTCH1 locus in NCI-H510A cells (Fig. 3A), the peak of which overlapped with a peak in LSD1 binding, suggesting that LSD1 may regulate H3K27Ac at this site (Fig. 3A). We also found increased NOTCH1 locus H3K27Ac upon ORY-1001 treatment in cells from the highly sensitive FHSC04 PDX model treated ex vivo with 1 nM ORY-1001 for 48 hours (Fig. 3B), which correlated with the changes seen in NOTCH1 abundance at both the mRNA and protein levels. The less sensitive NCI-H526 cell line did not display any H3K27Ac changes at the NOTCH1 locus in response to ORY-1001 treatment (Fig. 3A), and the lack of H3K27Ac changes was consistent with a failure to activate NOTCH1 in this line (fig. S3). REST expression also increased in our PDX ex vivo studies upon ORY-1001 treatment (Fig. 2, E, G, and H). ChIP-seq analyses revealed a substantial LSD1 peak around the REST transcriptional start site, which was associated with the H3K27Ac peak in the NCI-H510A SCLC cell line (fig. S4). These findings were confirmed by ChIP-PCR in SCLC cell lines and in the FHSC04 model ex vivo (Fig. 3, C and D). Thus, LSD1 inhibition with ORY-1001 leads to up-regulation of NOTCH1 and REST expression, which correlates with increased H3K27Ac at sites of prominent LSD1 binding in SCLC cells.

Fig. 3 Differential histone acetylation of LSD1-regulated genes.

(A) Read density tracks, visualized using University of California, Santa Cruz (UCSC) genome browser, of normalized ChIP-seq for H3K4me2 (black), H3K27Ac (red), and LSD1 (blue) in NCI-H510A and NCI-H526 cell lines. Cells were treated with vehicle (VEH) or 1 nM ORY-1001 for 96 hours. Shaded area highlights region in NOTCH1 with LSD1 binding and increased H3K27Ac upon ORY-1001 treatment in the NCI-H510A cell line. (B) Read density tracks of normalized ChIP-seq for H3K27Ac in cells derived from FHSC04 PDXs, a markedly ORY-1001–responsive model. Cells were treated ex vivo with vehicle or 1 nM ORY-1001 for 48 hours. Shaded area highlights region in NOTCH1 with increased H3K27Ac. (C and D) ChIP-PCR validation of H3K27Ac changes in NOTCH1, REST, ASCL1, and, as a control, ACTB in vehicle in SCLC cell lines treated for 96 hours (C) or FHSC04 cells treated for 48 hours (D) with vehicle or 1 nM ORY-1001 for 96 hours. Data are means ± SD from n = 3 experiments.

The LSD1-NOTCH-ASCL1 axis is important for SCLC cell viability

To investigate the relationship between LSD1, NOTCH, and ASCL1 in SCLC cells, we used genetic perturbation studies. Lentiviral short hairpin RNA (shRNA)–mediated knockdown of LSD1 in neuroendocrine SCLC cell line NCI-H510A resulted in increased abundance of NOTCH1 and decreased abundance of ASCL1 (Fig. 4A). Knockdown of LSD1 also led to reduced cell viability, as assessed by the CellTiter-Glo assay (Fig. 4B). The functional importance of decreased ASCL1 abundance was evaluated by shRNA-mediated knockdown. Two independent ASCL1-targeting shRNAs reduced protein abundance and led to a decrease in viability in NCI-H510A cells (Fig. 4, C and D, left panels). The FHSC04 PDX model is also amenable to lentiviral vector infection when grown ex vivo; in this model, genetic knockdown of either LSD1 or ASCL1 also resulted in decreased cell viability (Fig. 4, A to D, right panels). The role of NOTCH1 activation in SCLC cell survival was assessed in the FHSC04 model using an inducible system to overexpress N1ICD (Fig. 4E). Doxycycline-induced expression of N1ICD led to substantial suppression of ASCL1 and decreased cell viability, denoted by an increase in cleaved caspase 3 (Fig. 4E) and a significant decrease in cell proliferation (Fig. 4F). Thus, genetic perturbation of LSD1, NOTCH1, and ASCL1 supports the relevance of an LSD1-NOTCH-ASCL1 axis as a functional regulator of tumorigenesis in SCLC.

Fig. 4 Genetic perturbation of LSD1, ASCL1, and NOTCH1 in SCLC cells.

(A) Immunoblot analysis of the indicated proteins in response to lentiviral LSD1 knockdown in the NCI-H510A SCLC cell line and the FHSC04 PDX model ex vivo. ACTB is used as a loading control. Blots are representative of two independent experiments. (B) Proliferation analysis using CellTiter-Glo in response to LSD1 knockdown, analyzed as summarized below. (C) Immunoblot analysis of the indicated proteins in response to ASCL1 knockdown in the NCI-H510A SCLC cell line and the FHSC04 PDX model ex vivo. An ORY-1001–treated FHSC04 protein extract is used as a positive control for NOTCH1 and REST. Blots are representative of two independent experiments. (D) Proliferation analysis in response to ASCL1 knockdown, as in (B). RLU, relative light units. (E) Immunoblot analysis of the indicated proteins in FHSC04TetR cells in response to an inducible expression of N1ICD [doxycycline (Dox; 1 μg/μl) for 96 hours]. (F) Growth curve analysis of FHSC04TetR in response to N1ICD expression. All data are means ± SD from n = 3 experiments. *P < 0.05, **P < 0.01, and ***P < 0.005 by a two-tailed unpaired Student’s t test.

Pharmacological inhibition of NOTCH signaling partially prevents ORY-1001–mediated SCLC growth suppression

To determine whether activation of NOTCH signaling is important for antitumorigenic effects of ORY-1001, we took advantage of well-characterized γ-secretase inhibitors (GSIs). GSIs target NOTCH1-4 receptor activation resulting in the pan NOTCH signaling inhibition (26). We tested the effect of two GSIs, dibenzazepine (DBZ) (27) and RO4929097 (28), each in combination with ORY-1001. For these experiments, we chose two SCLC cell lines and two ex vivo PDX models that displayed activation of NOTCH signaling in response to ORY-1001. Treatment with either DBZ or RO4929097 inhibited NOTCH signaling that was induced by ORY-1001, as demonstrated by the lack of abundance of N1ICD and key NOTCH target gene product HES1 (Fig. 5, A and B). ORY-1001–induced suppression of ASCL1 abundance was at least partially prevented in the presence of either GSI compound (Fig. 5A). In addition, GSI treatment partially rescued ORY-1001–induced cell death ex vivo in drug-sensitive FHSC04 PDX-derived cells (Fig. 5C), indicating that NOTCH activation is critical to the cytotoxic action of ORY-1001. In accordance, GSI-treated cells were less sensitive to ORY-1001; IC50 values for ORY-1001 and cell viability both markedly increased in the presence of either GSI compound (Fig. 5, C and D). Likewise, the amount of ORY-1001–induced apoptosis, as detected by the abundance of cleaved PARP, decreased in cells treated in the presence of GSIs (Fig. 5E). Together, these results highlight a key role for NOTCH signaling in regulating ASCL1 suppression and the response to ORY-1001. These assays (Fig. 5) assessed adherent FHSC04 cells ex vivo, which, like FHSC04 suspension cells, exhibited strong neuroendocrine features and marked sensitivity to ORY-1001 (fig. S5).

Fig. 5 Pharmacological inhibition of NOTCH signaling partially rescues effects of ORY-1001.

(A) Immunoblot analysis of the indicated proteins in response to ORY-1001 (1 nM) with or without the GSIs RO4929097 or DBZ (0.5 μM) for 48 hours in SCLC cell lines NCI-H1417 and NCI-H69 and ex vivo PDX models MSK-LX227C and FHSC04. ACTB is used as a loading control. Blots are representative of two independent experiments. (B) Immunoblot analysis of HEY1 and HES1 abundance in adherent FHSC04 cells treated as in (A). Data are means ± SD from n = 3 experiments. **P < 0.01 and ***P < 0.005 by a two-tailed unpaired Student’s t test. (C) Dose-response curves in adherent FHSC04 cells treated ex vivo for 120 hours. Viability was quantified relative to vehicle control using the CellTiter-Glo assay. Data are means ± SD from n = 4 biological replicates, each with three technical replicates. (D) An extension of (C), showing the viability of FHSC04 cells in response to ORY-1001 at the 10 nM dose, alone and in the presence of RO4929097 or DBZ (0.5 μM), with comparison to each single GSI alone and vehicle. Data are means ± SD from n = 4 experiments, each with three technical replicates. **P < 0.01 and ****P < 0.0001 by a two-tailed unpaired Student’s t test. (E) Immunoblot analysis of cleaved PARP in FHSC04 cells in response to 96-hour treatment with ORY-1001 (10 nM) alone or with RO4929097 or DBZ (0.5 μM). Blots are representative of two independent experiments.

ORY-1001 is effective in PDX models of SCLC in vivo

The efficacy of ORY-1001 was next evaluated in vivo using seven SCLC PDX models (Fig. 6A and fig. S6). PDX-bearing nonobese (NOD) severe combined immunodeficient (SCID) γ (NSG) mice were orally administered ORY-1001 (at 400 μg/kg) or saline once weekly. Histological analysis of a panel of organs from ORY-1001–treated and saline control NSG mice revealed no evident tissue injury associated with the oral administration of ORY-1001 for 3 weeks (fig. S7). Western blot analysis of the PDX models revealed that six of the seven were ASCL1 positive, with only the JHU-LX33 model lacking ASCL1 expression (fig. S6C). ORY-1001 showed tumor inhibitory effects in all six of the ASCL1-positive PDX models tested (Fig. 6A and fig. S6, A and B). In each of these models, we observed tumor growth inhibition, and five of the six ASCL1-positive models exhibited significant reduction in the time it took tumors to grow to six times their initial volume (Fig. 6A and fig. S6B). JHU-LX33, the only model lacking ASCL1 expression (Fig. 2E and fig. S6C), was unresponsive to ORY-1001 (Fig. 6A, bottom), consistent with the hypothesis that ASCL1 expression is a potential biomarker for ORY-1001 responsiveness. PDX model FHSC04 exhibited complete tumor regression with ORY-1001 monotherapy, which occurred after about two doses of ORY-1001 given within 2 weeks (Fig. 6A, top). Responses remained durable in this model after treatment cessation at 21 days; 6 of 10 animals remained tumor free for the duration of the study, and tumor growth delay in the remaining four animals ranged from 80 to 299 days posttreatment end (Fig. 6B). The effects of ORY-1001 treatment were compared to SCLC standard of care, cisplatin-etoposide (CIS-ETO) (Fig. 6C). Again, ORY-1001 treatment resulted in rapid regression of SCLC to a nonpalpable state, whereas CIS-ETO resulted in modest tumor inhibition. CIS-ETO treatment resulted in significant body weight loss, which was not observed with the more effective ORY-1001 treatment (Fig. 6C, right). FHSC04 tumors treated with ORY-1001 were evaluated by immunohistochemistry for phospho-Ser10 histone H3 (PH3) and TUNEL (terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end labeling) staining to quantify proliferation and apoptosis, respectively. PH3 staining showed no significant changes in the proportion of mitotic cells; however, TUNEL analyses revealed significantly increased cell death in ORY-1001–treated tumors (Fig. 6D). ORY-1001 treatment therefore has the potential to induce a proapoptotic response in highly sensitive populations of patients with SCLC similar to the FHSC04 PDX model.

Fig. 6 ORY-1001 efficacy in PDX models of SCLC.

(A) Tumor growth inhibition curves over the treatment period (left) and Kaplan-Meier curves (right) showing time to reach 6× initial tumor volume (ITV) across six PDX models of SCLC treated with ORY-1001 (400 μg/kg once weekly) or with saline. Mice were treated with saline or ORY-1001 once tumors reached 150 mm3. Data are means ± SEM; n = 10 animals total per treatment group for FHSC04 (pooled from two experiments, each with n = 5 per group); for all others, n = 5 to 6 per group. Tumor growth curves: *P < 0.05, **P < 0.005, and ***P < 0.0005 by two-way analysis of variance (ANOVA) with Sidak’s posttest. Kaplan-Meier curves show P value from log-rank test. (B) Tumor volume plots for mice in FHSC04 model treated with saline or ORY-1001 depicted in (A) extending beyond treatment end at 21 days (solid line). Mouse tumor volumes are individually plotted for response and durability of tumor regressions. (C) Repeat of ORY-1001 treatment in FHSC04 with comparison to a CIS-ETO combination therapy (left), n = 5 mice per treatment group. Change in body weight is shown (right) as CIS-ETO treatment led to reductions in body weight not seen with ORY-1001. Cisplatin was dosed at 5 mg/kg once per week and etoposide at 10 mg/kg every 3 days. (D) TUNEL and PH3 immunohistochemistry analysis to assess proliferation and cell death in FHSC04 PDXs collected 10 days after treatment initiation. n = 5 tumors per group; P value was assessed by Student’s t test. n.s., not significant. Scale bars, 6.5 μm. (E) Volcano plot showing differentially expressed genes in FHSC04 PDXs after 10 days’ treatment with ORY-1001 as identified using edgeR. n = 5 control and 5 ORY-1001–treated mice. Red, up-regulated genes; green, down-regulated genes; FDR < 0.01. (F) Western blot analyses and quantifications (bottom) of ASCL1 and NOTCH pathway protein abundance in FHSC04 PDX in vivo. Data are means ± SEM from n = 3 mice per group; tumors harvested 10 days after treatment initiation. ***P < 0.005 by a two-tailed unpaired Student’s t test.

To characterize genetic features of the exceptionally responding FHSC04 model, we performed copy number variation (CNV) analyses using low-coverage whole-genome sequencing and targeted resequencing of a panel of 509 cancer-mutated genes (Ovation Cancer2.0 panel, NuGEN). CNV analyses revealed many regions of chromosomal gains/losses and the absence of focal amplifications in MYC family members in FHSC04 (fig. S8A). Targeted resequencing (fig. S8B) revealed homozygous truncating nonsense mutations in RB1 and TP53 and a 1–base pair (bp) frameshift deletion in CREBBP, a gene that we recently demonstrated to function as an SCLC tumor suppressor (29). Western blot analyses confirmed complete loss of CREBBP protein in FHSC04 and also revealed that another model, JHU-LX110, which exhibited growth inhibition but not regression upon ORY-1001 treatment, also exhibited lack of CREBBP protein abundance (fig. S8C). FHSC04 also harbored a missense mutation of unknown relevance in NOTCH1 (T1379 M) and was wild type for known SCLC-mutated genes, including PTEN, KMT2D, and NOTCH2.

To better understand the molecular response to LSD1 inhibition in the highly sensitive FHSC04 in vivo model, we again performed RNA-seq analyses. edgeR was used to identify differentially expressed genes and revealed NOTCH1 pathway genes to be overexpressed upon 10 days of ORY-1001 treatment in vivo (Fig. 6E and fig. S9). NOTCH targets genes HES1, HEY1, and REST were among the top 15 differentially expressed transcripts identified (Fig. 6E, table S6, and fig. S9). GOseq analyses identified the NOTCH signaling pathway and regulation of nervous system development as among the significantly overrepresented terms (table S7). With ORY-1001 treatment, we observed decreased expression of neuroendocrine transcripts such as CALCA, GRP, and INSM1, as well as neuronal transcripts (e.g., RELN, NEURL1, and BDNF) (fig. S9). Similar to our ex vivo experiments, we found NOTCH1, NOTCH2, REST, and HES1 to be up-regulated at the protein level, whereas ASCL1 was suppressed with in vivo ORY-1001 treatment (Fig. 6F). Thus, the response to LSD1 inhibition in this drug-sensitive model included activation of the NOTCH pathway, suppression of ASCL1, and reduced expression of markers of neuroendocrine/neuronal lineages.


Although SCLC often shows strong initial responses to CIS-ETO, these effects are short lived and chemoresistance arises rapidly. There is an urgent need for improved SCLC therapies that take advantage of biological vulnerabilities recently identified in SCLC. LSD1 inhibition may prove to be an effective therapeutic strategy for SCLC by targeting chromatin to suppress neuroendocrine-specific differentiation pathways that SCLC cells rely upon for survival.

Our mechanistic studies demonstrate that ASCL1 suppression through NOTCH activation is important for the response to LSD1 inhibition in SCLC. ASCL1 is a transcription factor required for lung neuroendocrine cell development and SCLC cell viability. Ascl1 knockout mice die during development, and their fetal lungs completely lack neuroendocrine cells (30). Moreover, when Ascl1 is deleted in a mouse model of SCLC, marked suppression of tumorigenesis is observed in vivo (5). Tumor inhibitory effects are also observed in Ascl1 hemizygous animals, underscoring the importance of normal Ascl1 dosage for SCLC cell viability (5). Although the ASCL1 transcription factor is not classically druggable, this study shows that LSD1 inhibition provides a means to activate NOTCH family members, thus suppressing ASCL1 expression. An important finding in our PDX ex vivo and in vivo studies was that LSD1 inhibition in different models led to varied degrees of NOTCH pathway activation and ASCL1 suppression. LSD1 inhibition with ORY-1001 in the FHSC04 model resulted in a rapid and robust drop in ASCL1 protein along with stronger up-regulation of NOTCH than seen with less sensitive models. These results were confirmed with genetic experiments, substantiating that these effects of ORY-1001 represent on-target consequences of LSD1 inhibition. Knockdown of ASCL1 in FHSC04 resulted in reduced viability, consistent with a number of reports showing that ASCL1 suppression in SCLC leads to impaired neoplastic potential (5, 21). A previous study linked LSD1 inhibition with suppression of ASCL1 in SCLC cells (13). We now demonstrate that it is NOTCH activation downstream of LSD1 inhibition that results in ASCL1 suppression and that NOTCH regulation is functionally important for the apoptotic response to ORY-1001 (Fig. 4).

NOTCH pathway activation can be oncogenic in some contexts; however, in SCLC, NOTCH1 is frequently inactivated (2) and thought to function as a tumor suppressor. Overexpression of the N1ICD or N2ICD strongly inhibited tumor development in mouse SCLC models (2). These in vivo results are consistent with studies that found that NOTCH activation in SCLC cells impairs proliferation and suppresses ASCL1 (20, 21). Furthermore, during mouse development, NOTCH signaling inhibits the differentiation of lung neuroendocrine cells from precursor cells (6). Genetic links between LSD1 and NOTCH have been previously made in studies that used Drosophila as a model system (31). Notch target genes were derepressed in dLSD1-inactivating mutants, and genetic suppression of the Notch pathway could negate the developmental consequences of loss-of-function mutations in dLSD1 (31). In mammalian cells, intriguing connections between NOTCH and LSD1 have also been made. In cortical development, defects in neuronal migration caused by LSD1 suppression could be rescued by suppression of NOTCH (32). Physical interactions between LSD1 and NOTCH pathway components, such as RBPJ, have also been described (33). Our studies show that activation of NOTCH downstream of LSD1 inhibition is important for antitumorigenic effects of LSD1 inhibition in SCLC. Inhibition of LSD1 using ORY-1001 led to activation of NOTCH signaling, and the NOTCH pathway was one of the most substantially altered upon LSD1 inhibition in PDX models treated with ORY-1001 ex vivo. The activation of NOTCH1 after LSD1 inhibition did not appear to be mediated by changes in H3K4me2. Instead, we demonstrate that LSD1 bound to a region within the NOTCH1 gene associated with increased H3K27Ac upon ORY-1001 treatment. The LSD1 CoREST complex includes histone deacetylases HDAC1 and HDAC2, and an outstanding question is whether impairment of these deacetylases upon LSD1 inhibition contributes to NOTCH1 activation. An implication of our data is that key effects of LSD1 inhibition may be unrelated to methylation of H3K4. A lack of change in H3K4 methylation in response to LSD1 inhibition was also found in a recent study of AML, where an LSD1 inhibitor disrupted association between LSD1 and a transcriptional repressor (GFI1) to result in rapid changes in gene expression and increased H3K27Ac without changes in H3K4 methylation (34). It will be critical for future work to determine whether LSD1-interacting transcriptional repressors such as GFI1 [or INSM1 (13)] contribute to control of NOTCH1 expression in SCLC. The ability of LSD1 inhibition to activate the NOTCH pathway is likely to be highly context dependent. In embryonic stem cells, suppression of LSD1 was not associated with strong activation of NOTCH signaling (22). In contrast to SCLC, NOTCH signaling is oncogenic in T cell acute lymphoblastic leukemia cells, and LSD1 activates the NOTCH pathway under this context (35). In neuroendocrine SCLC, our data demonstrate that NOTCH signaling is activated in response to LSD1 inhibition, and this activation contributes to the antitumorigenic responses to ORY-1001.

On the basis of the heterogeneity in responses across different PDX models, it is critical that we better define the factors that contribute to ORY-1001 sensitivity. Our data show that LSD1 inhibition can consistently activate NOTCH signaling and suppress ASCL1 expression, pointing to a mechanism underlying LSD1 activity in SCLC. Our data do not support LSD1 inhibition for the small subset of SCLC that lacks expression of ASCL1, because the one ASCL1-negative PDX model tested (JHU-LX33) was the only model found to be completely nonresponsive. A key determinant of whether a tumor will respond well to LSD1 inhibition may be the magnitude of NOTCH activation and downstream suppression of ASCL1, which we found to differ greatly from tumor to tumor. Underlying reasons for different degrees of NOTCH activation in response to ORY-1001 in SCLC are to be explored. Genomic analyses on the exceptionally responsive model FHSC04 revealed the presence of a homozygous truncating deletion in CREBBP and loss of CREBBP protein (fig. S8). Future studies will determine whether mutations in CREBBP, or other features of FHSC04, could be used to help predict durable responses to ORY-1001 in patients with SCLC. LSD1 inhibition may augment immune responses (36), and it will be critical for future studies to use immune-competent models of SCLC to explore the impact of LSD1 inhibition on tumor immunity and response to immune checkpoint inhibitors. Overall, these results can inform future strategies that aim to enhance the activity of LSD1 inhibitors in SCLC through combination therapies that further act to increase NOTCH activity and/or decrease ASCL1 expression to induce synergistic antitumor effects.

The highly potent and selective LSD1 inhibitor ORY-1001 shows a robust antitumor effect in PDX models of SCLC with a favorable safety profile. An exceptional response to ORY-1001 occurred in the PDX model FHSC04, which was derived from a chemoresistant patient with SCLC. In this model, we observed complete and durable regression in response to ORY-1001 monotherapy for the duration of the experiment. Given this finding, patient selection to identify potential exceptional responses will be essential to maximize and sustain the clinical benefit of LSD1 inhibitors. Identification of key genetic and epigenetic features of exceptionally responsive SCLC could help direct LSD1 inhibitors to patients with the most clinical benefit.


Experimental design

This study was designed to evaluate the response of SCLC tumor cells to LSD1 inhibition. We evaluated the response to a novel LSD1 inhibitor, ORY-1001, in SCLC cell lines, SCLC PDX models ex vivo, and SCLC PDX models in vivo. We designed experiments to understand the mechanisms underlying responses to ORY-1001. This included genetically perturbing candidate drivers of response to ORY-1001 in SCLC cells and PDX models studied ex vivo. All mouse experiments included the random assigning of mice into treatment groups at the time of the initial expansion of the PDX model. In vivo experiments were not performed blinded. Mouse experiments were stopped at a predetermined end date that differed from 3 to 5 weeks of treatment (dependent on the kinetics of the model), earlier if tumors reached a maximum diameter of 2 cm or if poor mouse body condition or tumor ulceration necessitated euthanasia. The number of replicates and statistical analyses are reported below and in the figures. No data points were removed as outliers.

Broad cell line panel screen

The activity of ORY-1001 was assessed in a panel of 275 cell lines. All cell lines were grown in medium conditions recommended by the American Type Culture Collection (ATCC) and plated 24 hours before compound addition. The end point of cell viability was assessed after 96 hours in culture with ORY-1001 using the CellTiter-Glo assay according to the manufacturer’s protocol (Promega). The assay was performed in a 384-well plate format with a final volume of 40 μl. Cell lines were treated with 2 μl of single agent at 1:2 dilutions for a total of 18 doses including the vehicle-only control. ORY-1001 and controls, 17-AAG and paclitaxel, were assessed at a maximum dose of 50 μM concentration diluted in 2% dimethyl sulfoxide or phosphate-buffered saline (PBS). The percentage of antiproliferative activity was calculated using the following formula: [1 − (T − B)/(C − B)] × 100 (%), where T− is the sample at each concentration, B is the no CellTiter-Glo control, and C is the vehicle control. Data were fit with a four-parameter equation using XLfit to generate a concentration-response curve, and relative EC50 values were determined.

PDX model generation and expansion

Animal experiments were performed at the Fred Hutchinson Cancer Research Center following Institutional Animal Care and Use Committee–approved protocols. The generation of PDX models from SCLC patient CTCs followed protocols approved by the Fred Hutchinson Institutional Review Board, and patients provided informed consent for inclusion in the study. Three PDX models (FHSC04, FHSC14, and FHSC36) were generated from blood samples obtained from patients with extensive-stage SCLC, following the methodology described by the Dive Laboratory (37). FHSC14 was from a chemonaïve patient, whereas FHSC04 and FHSC36 were from patients who had previously relapsed after first-line chemotherapy. Briefly, blood (7.5 ml) from each patient was enriched for CTCs using the RosetteSep CTC Enrichment Cocktail Containing Anti-CD36/Anti-CD45, which enriches for circulating epithelial tumor cells from whole blood based on CD36/CD45-negative selection. The CTC-enriched mononuclear layer of peripheral blood was isolated using Ficoll-Paque separation medium. The isolated mononuclear cell layer was washed (1:10 HITES:Hanks’ balanced salt solution), and the resulting cell pellet was suspended 1:1 by volume in Matrigel and HITES media and injected into the left flank of NSG mice under isoflurane anesthesia. The initiation and characterization of additional PDX models used in this study (JHU-LX48, JHU-LX108, JHU-LX110, and JHU-LX33) have been described previously (1618).

To propagate PDX models, resected tumors were digested in 25 ml of collagenase from Clostridium (1 mg/ml) in PBS for 45 min at 37°C with occasional agitation by vortexing to dissociate tissue. To dissociate tissue to a single-cell suspension, tissue fragments were diluted 1:1 with RPMI 1640 medium containing penicillin (100 U/ml) and streptomycin (100 μg/ml), strained through a 70-μm strainer, and centrifuged at 1250g for 10 min. The resulting pellet was resuspended in 20 ml of RPMI 1640 and strained through a 40-μm strainer. Dissociated cells were suspended 1:1 by volume in Matrigel and HITES media at a concentration of 1 × 106 cells per 100 μl final volume per injection site. Cells were implanted using a 28.5-gauge syringe, unilaterally, in the left flank of NOD SCID interleukin-2 receptor γ-deficient (NSG) mice, under isoflurane anesthesia.

PDX drug treatment studies

Eight- to 12-week-old NSG mice were implanted with 1.0 × 106 disaggregated cells from one of seven PDX models (FHSC04, FHSC14, FHSC36, JHU-LX33, JHU-LX48, JHU-LX110, and JHU-LX108) in 100 μl of 1:1 HITES media:Matrigel. Once palpable, flank tumors were measured in two dimensions (length and width) using digital calipers, and volume was calculated using the formula for a prolate ellipsoid, length (mm) × width2 (mm)/2 = mm3. Once tumor volume reached 150 to 200 mm3, mice were randomly assigned to treatment groups for 21 to 35 days, depending on the kinetics of growth in the given model. Animals were treated with saline or with ORY-1001 (400 μg/kg; Roche), delivered by oral gavage once every 7 days, and dissolved to 10 ml/kg with 0.9% saline solution. For the 10-day treatment in FHSC04 used for molecular analyses, an additional dose of ORY-1001 (400 μg/kg) was given 4 hours before tissue collection. For the FHSC04 model in which complete tumor regressions were observed, ORY-1001–treated mice were monitored for tumor return off of treatment for an additional 300 days.

Histology and immunohistochemistry

Resected lung tumors and PDX tissue were fixed in neutral-buffered formalin for 48 hours before processing to paraffin. Paraffin blocks were sectioned to a thickness of 4 μm and stained with hematoxylin and eosin. Immunohistochemical analysis was performed using rabbit anti-PH3 antibody (1:300; EMD Millipore, catalog no. 06-570). Paraffin sections were processed from xylene through a graded ethanol series to PBS. Unmasking was performed using microwave heating in sodium citrate buffer (0.01 M at pH 6.0). Endogenous peroxidases were blocked with 3.5% H2O2, and immunohistochemical analysis was performed with overnight incubation in primary antibody at 4°C. Biotin-conjugated secondary antibodies (Vector Laboratories) were used at a dilution of 1:100, and detection was done via a biotin-peroxidase complex (Vectastain ABC; Vector Laboratories) with 3,3′-diaminobenzidine (DAB) substrate (Vector Laboratories). TUNEL assays were carried out according to the manufacturer’s instructions using the in situ cell death detection kit, POD (Roche, product no. 11684817910). Tissue was imaged on a Nikon E800 microscope and quantified at 40× with three fields per tissue slice.


Two-way ANOVA was carried out to compare saline versus ORY-1001 treatment on tumor volume across the drug treatment period with day and treatment as factors. Significant effects were followed up with Sidak’s multiple comparisons test. Kaplan-Meier curves of time for tumor volume to reach six times initial tumor volume were generated using GraphPad Prism 7 (GraphPad Software), with a log-rank test to determine P values for significance. Immunohistochemistry was analyzed using Student’s t tests, comparing percentage of positive antibody-stained cells to the total number of cells in each field. For cell growth experiments, statistical significance was determined using a two-tailed unpaired Student’s t test.

Cell lines, culture, and reagents

SCLC cell lines were obtained from the ATCC. Cells were maintained in accordance to the ATCC guidelines. NCI-H69 and NCI-H1417 were cultured in RPMI 1640 supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), and 10% fetal bovine serum (FBS). NCI-H510A was cultured in DMEM (Dulbecco’s modified Eagle’s medium)–F12 supplemented with sodium pyruvate (1 mM), insulin-transferrin-selenium (10, 5.5, and 0.0067 μg/ml, respectively), 30 nM hydrocortisone, 10 nM β-estradiol, penicillin (100 U/ml), streptomycin (100 μg/ml), and 10% FBS. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. All lines were short tandem repeat–profiled for authentication. Ex vivo PDX models were cultured in DMEM-F12 supplemented with sodium pyruvate (1 mM), insulin-transferrin-selenium (10, 5.5, and 0.0067 μg/ml, respectively), 30 nM hydrocortisone, 10 nM β-estradiol, penicillin (100 U/ml), streptomycin (100 μg/ml), and 10% FBS. All experiments were performed on low-passage ex vivo PDX cultures. 293TN producer cell line was cultured in DMEM supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), and 10% FBS.

Lentivirus vector production, concentration, and generation of stable lines

For lentiviral knockdown experiments, shRNA sequences targeting LSD1, ASCL1, and NOTCH1 were selected and cloned into pLKO.1 puro vector (Addgene plasmid no. 8453) according to The RNAi Consortium recommendations ( A complete list of shRNA sequences can be found in table S8. Lentiviral vectors were produced by cotransfecting 293TN producer cells with the lentiviral vectors and helper plasmids psPAX2 (Addgene plasmid no. 12260) and pMD2.G (Addgene plasmid no. 12259; ratio, 1:1:0.67) using a calcium phosphate protocol. Viral supernatants were collected at 64 hours after transfection, filtered, and concentrated through a Stericup-HV polyvinylidene difluoride 0.45-μm filter. Virus was resuspended in 1× sterile PBS. Viral transductions were performed for 16 to 24 hours in the presence of polybrene (8 μg/ml). Equal viral titers were used. Puromycin selection was performed for 4 to 5 days, and stable lines were maintained with a minimal amount of puromycin (0.125 μg/ml). The FHSC04 TetR cells were generated by stable transduction of a TetR expressing lentiviral vector pLenti CMV TetR Blast (716-1) (Addgene plasmid no. 17492). A second transduction was performed to introduce a lentiviral vector expressing NOTCH1 NICD (NOTCH intracellular domain) or a control vector under the regulation of Tet operator CMV promoter. The pLenti-puro NOTCH1 NICD was generated by PCR amplifying the NOTCH1-NICD complementary DNA (cDNA) from TetO-FUW-NICD (Addgene plasmid no. 61540) and cloning into pLenti-Puro (Addgene plasmid no. 39481) using the Spe I and Mlu I restriction sites.

Reverse transcription quantitative PCR

For ex vivo PDX samples, RNA was extracted in TRIzol (Invitrogen) and isolated according to the manufacturer’s protocol. cDNA was generated using an iScript synthesis kit (Bio-Rad) according to the manufacturer’s protocol. Quantitative PCR (qPCR) experiments were run on a Bio-Rad qPCR instrument (CFX384). Data were normalized to glyceraldehyde-phosphate dehydrogenase. A list of all the primers used for reverse transcription qPCR can be found in table S9.

Drug treatment effects on cell proliferation and viability

To monitor proliferation, cells were seeded at 10,000 cells per well in 96-well plates. Live cell content was estimated using a CellTiter-Glo assay (Promega) according to the manufacturer’s protocol at the times indicated in the figure legends. For each experiment, ORY-1001 was resuspended in saline (vehicle) and used within 24 hours. Ex vivo ORY-1001 studies were performed in 96-well plates (10,000 cells per well) for 120 hours. CellTiter-Glo was used to determine the relative cell content and viability. GSIs RO4929097 and DBZ were purchased from Selleckchem and used at 0.5 μM.

Growth curve analyses

Cells were plated in 12-well plates on day 0 in the presence or absence of doxycycline (1 μg/ml). Doxycycline was replenished every 2 days. Every 4 days, the number of cells was counted using an automated Z2 Series Coulter Counter (Beckman Coulter), and the same number of cells was replated for further counts. Experiments were carried out for a total of 12 days. Population doublings were calculated using the following formula: n = 3.32 (log UCY − log l) + X, where n is the final population doubling at end of a given subculture, UCY is the cell yield at that point, l is the cell number used as inoculum to begin that subculture, and X is the doubling of the inoculum used to initiate the subculture being quantitated.

Western blot analysis

Whole-cell protein extracts were prepared in cold cell lysis buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 0.5% sodium deoxycholate, and 5 mM EDTA] supplemented with protease and phosphatase inhibitors. Proteins were quantified using BCA protein assay, resolved on SDS–polyacrylamide gel electrophoresis gels (4 to 20%), and transferred to nitrocellulose membranes. Alternatively, cells were counted and directly resuspended in Laemmli buffer (1×). Protein samples were normalized to either tubulin or β-actin. A detailed list of antibodies used in the study can be found in table S10.

ChIP-seq experiments

Cells were treated with ORY-1001 or controls at the indicated time frame and concentration. Cell pellets were submersed in 1% formaldehyde in PBS, capped, and agitated at room temperature for 15 min. Fixation was stopped by the addition of 0.125 M glycine (final concentration). Cell pellets were washed twice with PBS, IGEPAL (0.5%), and phenylmethylsulfonyl fluoride (1 mM) and kept on ice for the remainder of the procedure. Chromatin was isolated by the addition of lysis buffer. Lysates were sonicated, and the DNA was sheared to an average length of 300 to 500 bp. Genomic DNA (input) was prepared by treating aliquots of chromatin with ribonuclease (RNase), proteinase K, and heat for decross-linking, followed by ethanol precipitation. Pellets were resuspended, and the resulting DNA was quantified on a NanoDrop spectrophotometer. Extrapolation to the original chromatin volume allowed quantitation of the total chromatin yield. Aliquots of chromatin (20 to 30 μg) were precleared with protein A agarose beads (Invitrogen). Genomic DNA regions of interest were isolated using 5 μl of antibody against LSD1 (Cell Signaling Technology, product no. 2184) or 4 μg of antibody against H3K27Ac (Active Motif, catalog no. 39133) and H3K4me2 (Active Motif, catalog no. 39679). Complexes were washed, eluted from the beads with SDS buffer, and subjected to RNase and proteinase K treatment. Cross-links were reversed by incubation overnight at 65°C, and ChIP DNA was purified by phenol-chloroform extraction and ethanol precipitation. Samples were subjected to subsequent Illumina sequence analysis, or qPCR reactions were carried out by Active Motif in triplicate using SYBR Green Supermix (Bio-Rad, catalog no. 170-8882) on a CFX Connect Real-Time PCR system, using the probes indicated in table S9. Data are reported as “binding events per 1000 cells,” which considers chromatin input, ChIP volumes, and primer pair efficiencies. Illumina sequencing libraries were prepared from the ChIP and input DNAs by the standard consecutive enzymatic steps of end-polishing, dA-addition, and adaptor ligation. After a final PCR amplification step, the resulting DNA libraries were quantified and sequenced on Illumina’s NextSeq 500 (75-bp single-ended reads). Reads were aligned to the human genome (hg19) using Burrows-Wheeler Aligner (38) with default settings. Duplicate reads were removed, and only uniquely mapped reads (mapping quality, ≥25) were used for further analysis. Alignments were extended in silico at their 3′ ends to a length of 200 bp, which is the average genomic fragment length in the size-selected library and assigned to 32-bp bins along the genome. The resulting histograms (genomic “signal maps”) were stored in bigWig files. Drosophila genome spike-in was used to downsample and normalize tag counts for comparisons across treated and untreated samples (ChIP Normalization Strategy; Active Motif) (39).

RNA-seq analyses

For RNA-seq analyses using PDX samples in vivo and ex vivo, the Ultra RNA Library Prep Kit for Illumina (New England BioLabs, catalog no. E753L) was used to generate libraries from total RNA. All library preparation was conducted according to the manufacturer’s instructions. Single-end sequencing (50 bp) was performed using an Illumina HiSeq 2500, and reads of low quality were filtered before alignment to the hg19 genome build using TopHat v2.0.12 (40). In vivo PDX samples were also aligned to mm9, where the mouse and human alignments from a given sample were compared, discarding from downstream analysis those reads that had fewer mismatches to mouse, relative to human. Cuffdiff v2.1.1 (41) was used to generate FPKM expression values. Counts were generated from TopHat alignments using the Python package HTSeq v0.6.1 (42) using the “intersection-strict” overlap mode. Genes with low counts across conditions were discarded before identification of differentially expressed genes using the Bioconductor package edgeR, v3.16.5 (43). An FDR (44) method was used to correct for multiple testing, where differentially expressed genes were identified with the FDR set at 5%. GOTERM_BP_DIRECT ontologies were acquired from DAVID v6.8 (45) and used with the Bioconductor package GOseq v1.26.0 (19) to identify overrepresented genes that were either significantly up- or down-regulated, applying an FDR method to correct for multiple testing (44). For RNA-seq analyses using human SCLC cell lines (Fig. 1), RNA libraries were prepared from total RNA using poly-A TruSeq Illumina kits and also sequenced using an Illumina HiSeq 2500. One hundred nanograms of mRNA was used per cell line. Raw reads were aligned against the hg19 genome using GSNAP (46) following recommended options for RNA-seq data. Resulting SAM files were converted to sorted BAM files using SAMtools. Gene expression values were calculated both as FPKM values and as read counts. Normalized read counts were obtained using the R package DESeq2 (47). An offset of 1 was added to each normalized expression value before log transformation and import into GenePattern v3.9.4 (48), where a row-based (gene-wise) z-score normalization was applied, followed by generation of a heat map (Fig. 1).


Fig. S1. Generation and characterization of an SCLC PDX model derived from isolated CTCs.

Fig. S2. NOTCH pathway marker changes in PDXs treated ex vivo with ORY-1001.

Fig. S3. Lack of NOTCH1 activation in NCI-H526 cells in response to ORY-1001.

Fig. S4. LSD1 binding and histone modification at REST locus in response to ORY-1001 in SCLC.

Fig. S5. Effects of ORY-1001 in nonadherent and adherent populations of FHSC04 cells.

Fig. S6. ORY-1001 efficacy and ASCL1 abundance in SCLC PDX model FHSC36.

Fig. S7. Toxicity analysis of in vivo responses to ORY-1001.

Fig. S8. Genomic alterations in PDX model FHSC04.

Fig. S9. Gene expression changes in FHSC04 in vivo in response to ORY-1001.

Table S1. ORY-1001 inhibits proliferation in a subset of SCLC cell lines.

Table S2. DEseq2 analysis of differentially expressed transcripts in ORY-1001–treated SCLC cell lines.

Table S3. Characteristics of the PDX models.

Table S4. edgeR analysis of differentially expressed transcripts in ORY-1001–treated PDX SCLCs.

Table S5. GO analysis of ORY-1001–treated PDXs.

Table S6. edgeR analysis of ORY-1001–treated FHSC04 PDX tumors.

Table S7. GO analysis of ORY-1001–treated FHSC04 PDX tumors.

Table S8. shRNA sequences.

Table S9. Primer sequences for qPCR.

Table S10. Antibodies.


Acknowledgments: We acknowledge assistance from the Fred Hutch Genomics and Bioinformatics Shared Resource and the Histopathology Shared Resource. Funding: D.M. acknowledges research support from Roche, from NIH/NCI grants R01CA197867 and R01CA200547, from a Seattle Translational Tumor Research grant, and from the Fred Hutch/University of Washington Cancer Consortium Support Grant P30CA015704. A.A. acknowledges support from the Lung Cancer Research Foundation/Uniting Against Lung Cancer. NIH/NCI training grants T32CA009657 and T32CA080416 supported E.E. and E.G., respectively. D.M. and J.T.P. acknowledge support from the Bonnie Addario Lung Cancer Foundation. J.T.P. and C.M.R. acknowledge support from the VARI-SU2C Epigenetics Dream Team Award. Author contributions: A.A. and E.E. designed and executed experiments; collected, analyzed, and interpreted data; and contributed to writing the manuscript. A.H.I., N.W., E.G., and F. Milletti designed and executed experiments and analyzed and interpreted data. R.B. and W.-Y.C. performed bioinformatic analyses. D.L. analyzed histopathology. K.D.E. and R.M. provided patient samples for PDX model generation. J.T.P. and C.M.R. provided critical PDX models and contributed to the writing of the manuscript. D.M. and F. Mack designed the study, analyzed and interpreted data, and wrote the manuscript. All authors reviewed and provided input on the contents of the manuscript. Competing interests: D.M. received research support from Roche that partially supported costs of this research. F. Milletti, W.-Y.C., and F. Mack are employees of Roche. C.M.R. has consulted with Roche and Celgene regarding anticancer drug development. The other authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper or the Supplementary Materials. The PDX models used here are available from Fred Hutchinson and from Memorial Sloan Kettering Institute under a material transfer agreement. Genomic datasets have been submitted to Gene Expression Omnibus under the SuperSeries accession number GSE103097.
View Abstract

Navigate This Article